Ep. 301: “Cell Fate Decisions in Cancer” Featuring Dr. Mark Hatley
Description
Guest:
Dr. Mark Hatley is an Associate Faculty Member and Director of the Division of Molecular Oncology at St. Jude Children’s Research Hospital. His research focuses on the developmental origins and genetic mechanisms of pediatric rhabdomyosarcoma. He talks about his work on pediatric oncology and the mechanisms that differentiate normal development from cancer. He also discusses the role of PAX3-FOXO1 and DICER1 in tumorigenesis. (37:50 )
Featured Products and Resources:
- Share your feedback and enter to win a Bluetooth speaker!
- Get a free wallchart that explains the functions, properties, and identifying markers of MSCs.
The Stem Cell Science Round Up
Transplanting Allogeneic Beta Cells – Researchers transplanted genetically modified allogeneic donor islet cells into a man with long-standing type 1 diabetes. (1:37 )
Pig Liver Xenotransplantation – RNA sequencing highlights how innate immune cells may affect thrombotic and immune pathways after liver xenotransplantation. (12:03 )
Chemical Reprogramming – A new method generates hCiPS cells from both cord blood and adult peripheral blood cells. (21:10 )
T Cell Development – Soluble Notch agonists support T cell development in suspension bioreactor culture. (27:30 )
Image courtesy of Dr. Mark Hatley
United States
